Amazon to build huge fulfillment center in Goochland County, creating 1,000+ jobs
The facility, to be located at 2022 Ashland Road, is expected to open in 2027. It will span 3.1 million square feet on a 107-acre parcel.
The fulfillment center, essentially a warehouse that stores smaller products like books and toys and completes orders for sellers with the help of robots, will be the fourth robotic center for the company in Virginia and its 10th facility in the larger Richmond area.
In 2023, Goochland County secured state and regional funding to construct a diverging diamond interchange at Route 623 and Interstate 64, according to an announcement from the Virginia governor's office. That interchange will be located less than a mile from Amazon's new facility and is expected to improve traffic slow and safety.
The Virginia Economic Development Partnership worked with Goochland County to secure the project, according to the governor's office.
'Amazon's continued expansion in Virginia is a testament to the collaboration between state, regional and local partners who are committed to smart, strategic growth,' Juan Pablo Segura, the state's new secretary of commerce and trade, said in a statement. 'This project is the result of long-term planning in Goochland County and strong infrastructure investments by the Commonwealth. Amazon's latest investment will bring significant economic opportunity to the region.'
Amazon (NASDAQ: AMZN) is putting the facility in a business district that Goochland calls the Rockville Opportunity Corridor. The area also includes the Luck Stone Rockville Quarry, the Martin Marietta – Anderson Creek Quarry, Vulcan Materials Co., Lanier Industrial Park and Midnight Brewery.
Since 2010, Amazon has invested more than $135 billion in Virginia, including infrastructure and employee compensation to employees, according to the governor's office, and has created more than 42,000 direct jobs in state.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Digital Trends
26 minutes ago
- Digital Trends
Blink's subscription model is affordable, but is it worth it?
Blink is the younger, more-affordable cousin of Ring. Both brands fall under the Amazon umbrella, and both work well (although I find that Ring is slightly faster in terms of loading times). Both brands have something else in common, too: to access the best features, you'll need a subscription. Blink offers three different tiers. With no subscription, you'll receive notifications whenever something moves within range of the camera and see an extended live view of up to five minutes. While the official site doesn't list the number of devices that includes, all of your connected Blink cameras and other devices will send motion alerts. Recommended Videos The next level is the Basic plan. That's $3 per month for a single device and includes cloud storage for up to 60 days, motion detection, person and vehicle detection, and an extended live view of up to 90 minutes. It also includes motion event recording, live view recording, instant video access, photo capture, and an auto-update thumbnail. The highest tier is called Plus. It's $10 per month for an unlimited number of devices and the best value by far. It includes everything the other plans have, with the addition of custom snooze notifications, a 10% discount off future Blink devices, extended warranty coverage, and the Blink Moments feature that stitches together multiple events into a seamless video. With those features in mind, you have to ask: is a Blink subscription really worth it? I'll be honest: I hate subscription services. If I buy a device, I want to be able to use all of its features without paying an arbitrary monthly sum. However, given the affordability of Blink devices in relation to other products on the market and just how many features the subscription opens up, the smart devices aren't worth their cost unless you pay for the subscription. I subscribe to the Plus tier. With a video doorbell and multiple cameras around the exterior of my home, it's a more economical choice than paying per device. And $10 per month (closer to $8 with the annual sub) is on-par with what other brands offer, although Blink does lack feature parity with more advanced options like Ring. Is $100 per year worth the cost? I paid next to nothing for my Blink devices. For full transparency, several devices were sent my way for review, but I have expanded the system with additional purchases. The kicker? I bought most of them during Prime Day or Black Friday sales. Blink has a tendency to drop its prices to an almost absurd degree. While I do have a few Ring products, I can usually get two or three Blink cameras for the price of a single Ring. The subscription cost feels like a small amount to pay given how well the system has worked. It lets me keep an eye on the house when I'm traveling, and it also lets my wife and me check in on our pets. The ability to view up to 90 minutes of footage at a time is a win, particularly when I suspect multiple events might be connected. For example, I had silenced my phone, only to check it later and see more than 30 motion alerts. That meant that either my neighbors were having a party and the camera was being set off by motion at the fringes of the yard, or our garden gnomes had decided to rise up and form an army. Thankfully, it was the former (although the garden gnome army would be fun to explain). Some kids were playing in the cul-de-sac and chased a ball into the yard, and that explained the alerts. That's another perk of the Plus tier: it allows you to snooze notifications for a set amount of time. When my lawn service comes to cut the grass, I tend to shut off notifications; otherwise, my phone will practically vibrate itself off the desk as the mower moves back and forth in its field of view. The downside: no professional monitoring Blink is strictly a DIY system. You can keep an eye on your property no matter where you are, but no one will intervene to alert the authorities if necessary. Ring offers that service, but it costs an extra $10 per month on top of their mid-tier plan, which means you're paying at least $20 (and more than likely $25) for professional protection. That's the trade-off. While $10 per month gives you access to a host of different features, it doesn't provide you with what is arguably the most useful one of all. I always suggest professional monitoring whenever possible, if only for the peace of mind — but if you don't have access to a device that offers that, then a monthly fee of $10 is a small price to pay, especially as it makes it significantly easier for you to keep an eye on what's happening around your home on your own. Pairing that subscription with some of Blink's optional accessories, like the solar panel or the floodlight attachment, gives you a home security system for a fraction of the cost of other names in the business.
Forbes
27 minutes ago
- Forbes
Amazon's App Store Decision—48 Hours To Delete Your Apps
You have been warned. Amazon has confirmed that 'starting August 20, 2025, you will no longer have access to the Amazon Appstore on your Android device.' That's just 48 hours from now. The retail giant says it will now focus its efforts on its own devices. For anyone who has installed an app from the store, this is a potential security threat and you need to act before the deadline. All apps must be deleted. Per Android Police, 'once no longer supported, apps downloaded via the Amazon Appstore "will not be guaranteed to operate on Android devices." That means no support, which not only risks apps becoming 'highly unstable' but also means any security vulnerabilities will not be patched. While Amazon's advice is to install replacement or replica apps from Google's Play Store, you actually need to do more than that. Any apps you may have installed from Amazon's store need to be deleted. If they remain on your phone in an unsupported state, then it outs your device and your data at risk. Amazon also confirms that 'we will also be discontinuing the Amazon Coins program on August 20, 2025.' Those who have used the store and still have Amazon Coins will see those refunded, albeit details on how and when that will be done seem scarce. Android users should focus on Play Store only for apps, it remains your best bet when it comes to security safeguards and works in tandem with Android's core OS and the Play ecosystem that underpins it. That includes Play Protect, which protects your phone from dangerous apps from any source. It's also worth noting that Google is pushing a wider clampdown in third-party stores with its new Advanced Protection Mode, albeit Amazon would no doubt have been seen as an official store for all phones had it continued longer term.
Associated Press
an hour ago
- Associated Press
Ascentage Pharma Announces Global Registrational Phase III Study of Lisaftoclax for First-line Treatment of Patients with Higher-Risk Myelodysplastic Syndrome Cleared by US FDA and EMA
ROCKVILLE, Md. and SUZHOU, China, Aug. 17, 2025 (GLOBE NEWSWIRE) -- Ascentage Pharma (NASDAQ: AAPG; HKEX: 6855), a global, commercial stage, integrated biopharmaceutical company engaged in the discovery, development and commercialization of novel, differentiated therapies to address unmet medical needs in cancer, announced that it has received clearance by the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) to conduct GLORA-4 study (NCT06641414), a global registrational Phase III study of lisaftoclax (APG-2575), a proprietary Bcl-2 inhibitor, in combination with azacitidine (AZA), for the treatment of patients with newly diagnosed higher-risk myelodysplastic syndrome (HR-MDS). This marks the second registrational Phase III study of lisaftoclax to receive clearance from both the FDA and EMA. The GLORA-4 study is simultaneously enrolling patients at participating centers in multiple countries, to accelerate the drug's path to potential market authorization. To date, lisaftoclax is the only Bcl-2 inhibitor being advanced in a registrational Phase III trial in higher-risk MDS globally. This study, if positive, may potentially end the longstanding treatment gap in higher-risk MDS, marking yet another major milestone in the global clinical development of lisaftoclax. Dr. Yifan Zhai, Chief Medical Officer of Ascentage Pharma, said, 'Globally, we still lack targeted therapies for first-line treatment of patients with higher-risk MDS, which represents a huge unmet clinical need. Currently, hypomethylating agents (HMA) and allogeneic hematopoietic stem cell transplantation (allo-HSCT) remain the primary treatment options for higher-risk MDS. In earlier studies, lisaftoclax has demonstrated promising clinical benefit and tolerability. The clearances of the GLORA-4 study by the U.S. FDA and EMA, coinciding with the approval by the China CDE, pave the way for lisaftoclax to potentially become the first Bcl-2 inhibitor approved globally for first-line treatment of higher-risk MDS and the first targeted therapy approved for this indication since the introduction of HMA, which fundamentally reshapes the treatment landscape.' The GLORA-4 trial is being conducted simultaneously in China, the U.S., and Europe. This will significantly accelerate the clinical development of lisaftoclax in MDS and accelerate the drug's path to potential market authorization. Moving forward, we will remain steadfastly committed to our mission of addressing unmet clinical needs in China and around the world, actively advancing our clinical programs for the benefit of more patients.' GLORA-4 is a multi-region, multi-center, randomized, double-blind Phase III trial designed to evaluate the efficacy and safety of lisaftoclax in combination with AZA compared to placebo plus AZA in newly diagnosed adult patients with higher-risk MDS. The study was originally approved by the China CDE in 2024. Currently, the study is enrolling patients globally, with the first patients already enrolled in China and Europe. Guillermo Garcia-Manero, MD, Chair of the Department of Leukemia, The University of Texas MD Anderson Cancer Center (MDACC), and Prof. Xiaojun Huang, MD, an academician of the Chinese Academy of Engineering, director of the Institute of Hematology at Peking University, and director of the Department of Hematology at Peking University People's Hospital, are global co-leading principal investigators of the study. MDS is a myeloid clonal disease originating from hematopoietic stem cells with strongly age-correlated characteristics. Global epidemiological data of MDS show an exponential increase in incidence with age (22/100,000 in the population aged over 65 years), with a median age of diagnosis of 70 years1. More than 75% of patients with MDS present a complex disease profile that includes at least two comorbidities2. The primary risk of MDS is clonal evolution leading to progression to acute myeloid leukemia (AML), with 40-60% of higher-risk patients (high/very high risk, as classified by IPSS-R) progressing to AML within five years3. These patients have a dismal prognosis and a median survival of less than six months4. As the standard first-line therapy for higher-risk MDS, HMAs offer inadequate responses to treatment, with an overall response rate (ORR) of just 30-40%5, a complete response (CR) rate of 10-17%, and a median duration of response of 9-12 months6, 8. While allo-HSCT can offer a potential cure, it is limited by the median age of patients, complex disease profiles, common depletion of the hematopoietic stem cell reserve, and a transplantation-related mortality (TRM) rate of 25-35%. As a result, only 5-10% of eligible patients can receive transplantation7. The five-year survival rate of patients who are classified by the IPSS-R as high-risk remains at 16-24%8, highlighting an urgent unmet medical need for innovative therapies that can change the treatment paradigm. Lisaftoclax is a proprietary, novel, orally administered Bcl-2 selective inhibitor being developed by Ascentage Pharma to treat patients with malignancies by selectively blocking the anti-apoptotic protein Bcl-2 and restoring the normal apoptosis process in cancer cells. Lisaftoclax is already approved in China for adult patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) who have previously received at least one systemic therapy, including Bruton's tyrosine kinase (BTK) inhibitors. Previously, the Company released the clinical data of lisaftoclax in combination with AZA in treatment-naïve (TN) MDS during the 2024 American Society of Hematology (ASH) Annual Meeting and the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting. These data showed an ORR of 75%, much higher than HMAs alone, which demonstrated the clinical benefit of the combination regimen. The combination also showed a favorable safety profile, with a low incidence of severe hematologic toxicities and neutropenia-related infections. In addition, the proportion of patients requiring dose adjustments was low and there were no treatment-related mortalities within 60 days9, 10. Professor Huang commented, 'Despite the significant advancement in the treatment of hematologic malignancies, higher-risk MDS remains a major clinical challenge because of a range of factors. First, the current standard of care treatment with HMAs only offers limited efficacy, with just about one-third of patients achieving a response to treatment. Second, no breakthrough therapies have emerged globally in the two decades since the introduction of HMAs. As a result, there is an unmet clinical need for targeted therapies for higher-risk MDS. The compelling response rate and manageable safety profile observed in earlier studies of lisaftoclax are very encouraging. We hope this global Phase III study has the potential to provide new insights that could benefit how we treat and manage higher-risk MDS.' Dr. Garcia-Manero commented, 'Higher-risk MDS is more prevalent in older populations and thus presents unique clinical challenges. These patients often have multiple comorbidities and depleted hematopoietic reserves, making them less tolerant of treatment with particularly high requirement for safety. Preliminary clinical data of lisaftoclax demonstrated notable clinical benefit, with low rates of treatment-related dose adjustments and mortalities while maintaining significant response rates. We hope these characteristics of lisaftoclax will make it a potentially superior treatment option for patients.' References: About Ascentage Pharma Ascentage Pharma (NASDAQ: AAPG; HKEX: 6855) is a global, commercial stage, integrated biopharmaceutical company engaged in the discovery, development and commercialization of novel, differentiated therapies to address unmet medical needs in cancer. The company has built a rich pipeline of innovative drug candidates that includes inhibitors targeting key proteins in the apoptotic pathway, such as Bcl-2 and MDM2-p53 and next-generation kinase inhibitors. The lead asset, olverembatinib, is the first novel third-generation BCR-ABL1 inhibitor approved in China for the treatment of patients with CML in chronic phase (CML-CP) with T315I mutations, CML in accelerated phase (CML-AP) with T315I mutations, and CML-CP that is resistant or intolerant to first and second-generation TKIs. It is covered by the China National Reimbursement Drug List (NRDL). The Company is currently conducting an FDA-cleared, global registrational Phase III trial, or POLARIS-2, of olverembatinib for CML, as well as global registrational Phase III trials for patients with newly diagnosed Ph+ ALL and SDH-deficient GIST. The second lead asset, lisaftoclax, is the first China-approved third-generation Bcl-2 inhibitor indicated for the treatment of adult patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) who have previously received at least one systemic therapy, including Bruton's tyrosine kinase (BTK) inhibitors. The Company is currently conducting 4 global registrational Phase III trials: the GLORA study of lisaftoclax in combination with BTK inhibitors in patients with CLL/SLL who were previously treated with BTK inhibitors for more than 12 months with suboptimal response; the GLORA-2 study in patients with newly diagnosed CLL/SLL; the GLORA-3 study in newly diagnosed elderly and unfit patients with AML; and the GLORA-4 study in patients with newly diagnosed higher-risk MDS. Leveraging its robust R&D capabilities, Ascentage Pharma has built a portfolio of global intellectual property rights and entered into global partnerships and other relationships with numerous leading biotechnology and pharmaceutical companies, such as Takeda, AstraZeneca, Merck, Pfizer, and Innovent, in addition to research and development relationships with leading research institutions, such as Dana-Farber Cancer Institute, Mayo Clinic, National Cancer Institute and the University of Michigan. For more information, visit Forward-Looking Statements This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements, other than statements of historical facts, contained in this press release may be forward-looking statements, including statements that express Ascentage Pharma's opinions, expectations, beliefs, plans, objectives, assumptions or projections regarding future events or future results of operations or financial condition. These forward-looking statements are subject to a number of risks and uncertainties as discussed in Ascentage Pharma's filings with the SEC, including those set forth in the sections titled 'Risk factors' and 'Special note regarding forward-looking statements and industry data' in its Registration Statement on Form F-1, as amended, filed with the SEC on January 21, 2025, and the Form 20-F filed with the SEC on April 16, 2025, the sections headed 'Forward-looking Statements' and 'Risk Factors' in the prospectus of the Company for its Hong Kong initial public offering dated October 16, 2019, and other filings with the SEC and/or The Stock Exchange of Hong Kong Limited we made or make from time to time that may cause actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. The forward-looking statements contained in this presentation do not constitute profit forecast by the Company's management. As a result of these factors, you should not rely on these forward-looking statements as predictions of future events. The forward-looking statements contained in this press release are based on Ascentage Pharma's current expectations and beliefs concerning future developments and their potential effects and speak only as of the date of such statements. Ascentage Pharma does not undertake any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Contact Information Investor Relations: Hogan Wan, Head of IR and Strategy Ascentage Pharma [email protected] +86 512 85557777 Stephanie Carrington ICR Healthcare [email protected] +1 (646) 277-1282 Media Relations: Jon Yu ICR Healthcare [email protected] +1 (646) 677-1855
